The genomic landscape of young and old lung cancer patients highlights age-dependent mutation frequencies and clinical actionability in young patients.

Cai, Lei; Chen, Yong; Tong, Xiaoling; Wu, Xue; Bao, Hua; Shao, Yang; Luo, Zhuang; Wang, Xuming; Cao, Yang

Cai, Lei; Chen, Yong; Tong, Xiaoling; Wu, Xue; Bao, Hua; Shao, Yang; Luo, Zhuang; Wang, Xuming; Cao, Yang.

Afiliação

Cai L; Department of Thoracic Surgery, Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, China.
Chen Y; Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Zhejiang, Hangzhou, China.
Tong X; Department of Hepatobiliary Surgery, First Affiliated Hospital, Chongqing Medical University, Chongqing, China.
Wu X; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, Ontario, Canada.
Bao H; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, Ontario, Canada.
Shao Y; Translational Medicine Research Institute, Geneseeq Technology Inc., Toronto, Ontario, Canada.
Luo Z; Medical Department, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China.
Wang X; School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.
Cao Y; Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunan, China.

Int J Cancer ; 2021 Apr 02.

Article em En | MEDLINE | ID: mdl-33811322

Palavras-chave

EGFR; ERBB2; gene fusions; tyrosine kinase inhibitors; young lung cancer patients

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google